252 reports of this reaction
1.5% of all NEVIRAPINE reports
#15 most reported adverse reaction
PREMATURE BABY is the #15 most commonly reported adverse reaction for NEVIRAPINE, manufactured by Amneal Pharmaceuticals LLC. There are 252 FDA adverse event reports linking NEVIRAPINE to PREMATURE BABY. This represents approximately 1.5% of all 16,383 adverse event reports for this drug.
Patients taking NEVIRAPINE who experience premature baby should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PREMATURE BABY is a less commonly reported adverse event for NEVIRAPINE, but still significant enough to appear in the safety profile.
In addition to premature baby, the following adverse reactions have been reported for NEVIRAPINE:
The following drugs have also been linked to premature baby in FDA adverse event reports:
PREMATURE BABY has been reported as an adverse event in 252 FDA reports for NEVIRAPINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PREMATURE BABY accounts for approximately 1.5% of all adverse event reports for NEVIRAPINE, making it a notable side effect.
If you experience premature baby while taking NEVIRAPINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.